A smart insulin pen is an insulin delivery tool that offers some of the features of an insulin pump but without the always-connected experience required with pumps. A smart insulin pen can calculate each dose based on current blood sugar level, carbohydrate amounts, meal size, active insulin, and settings prescribed by patients doctor, deliver accurate half-unit doses, help prevent skipped or missed doses, send diabetes data to health care team whenever needed and work with patients smart phone or watch and popular diabetes data tracking platforms. Diabetes is a major public health problem that is approaching epidemic proportions globally, therefore, it is necessary to use smart insulin pens for a safe and effective administration of insulin to people suffering from Diabetes.

Market Dynamics

Key players operating in the market are focusing on acquisitions and partnerships, which is expected to drive the growth of the market over the forecast period. For instance, in February 2021, BIOCORP a company that designs, develops, manufactures delivery systems and innovative medical devices, entered into a partnership with Health2Sync, a Taiwan-based digital healthcare company, and SocialDiabetes, a Spain-based digital healthcare solution provider, for management of diabetes by integration of Mallya, a smart insulin pen cap manufactured by Biocorp with the digital applications developed by SocialDiabetes and Health2Sync. Furthermore, in September 2019, Sanofi S.A. and Abbott, a U.S.-based multinational medical devices and health care company, collaborated to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition. The two companies would focus on developing FreeStyle Libre technology with insulin dosing information for future smart pens, insulin titration apps, and cloud software.

Key features of the study

• This report provides in-depth analysis of the Latin America smart insulin pen market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Latin America smart insulin pen market based on the following parameters – Company Highlights, Types Portfolio, Key Highlights, Financial Performance, Market Strategies
• Key companies covered as a part of this study include Medtronic Plc., Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Owen Mumford Ltd., BIOCORP, Jiangsu Delfu medical device Co., Ltd., BERLIN-CHEMIE AG, and F. Hoffmann-La Roche AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Latin America smart insulin pen market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Latin America smart insulin pen market

Market Segmentation

• By Type (Revenue, USD Bn, 2021-2033)
  • First Generation
  • Second Generation
    • Bluetooth enabled pens
    • USB Connected pens
• By Usability (Revenue, USD Bn, 2021-2033)
  • Prefilled
  • Reusable
• By Indication (Revenue, USD Bn, 2021-2033)
  • Type 1 diabetes
  • Type 2 diabetes
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Key Players
  • Medtronic Plc
  • Sanofi S.A.
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Owen Mumford Ltd.
  • BIOCORP
  • Jiangsu Delfu medical device Co., Ltd.
  • BERLIN-CHEMIE AG
  • Hoffmann-La Roche AG